Jaing Tang-Her, Yang Chao-Ping, Hung Iou-Jih, Tsay Pei-Kwei, Tseng Chen-Kan, Chen Shih-Hsiang
Divisions of Hematology and Oncology, Department of Pediatrics, Chang Gung Children's Hospital, Taoyuan, Taiwan.
Pediatr Blood Cancer. 2005 Aug;45(2):135-8. doi: 10.1002/pbc.20316.
Patients with T-cell acute lymphoblastic leukemia (T-ALL) frequently present with unfavorable features at diagnosis. Therefore, they are considered to have a higher risk to relapse. We sought to correlate initial central nervous system (CNS) disease at diagnosis with shortened survival in childhood T-ALL.
A retrospective analysis of 48 children with T-ALL was performed. The group consisted of 32 boys and 16 girls whose median age was 8 years. Their CNS status was classified as CNS-1 (no blast cells in cerebrospinal fluid (CSF); n = 44), CNS-2 (<5 WBC/microl of CSF with blast cells; n = 0), or CNS-3 (> or =5 WBC/microl of CSF with blast cells or signs of CNS involvement; n = 4). For univariate prognostic analyses, we used the log-rank test to determine the influence of patient characteristics (age, sex, lymphomatous presentations, initial leukocyte count, CNS disease, and newer therapeutic strategies) on each point.
Complete remission was induced in 87.5% of patients. Median survival was 37 months, and 5-year overall survival and disease-free survival rates were 49.5% +/- 8.1% and 47.1% +/- 8.2%, respectively. Patients without initial CNS involvement seemed to have a trend toward longer overall survival (P = 0.036). Disease-free survival was not influenced by age, leukocyte count, or other factors analyzed.
Patients who present with initial CNS involvement have a prognosis worse than that of patients without CNS disease. The introduction of early and effective CNS-directed therapy might no longer portend a poor prognosis for CNS leukemia.
T 细胞急性淋巴细胞白血病(T-ALL)患者在诊断时常常呈现出不良特征。因此,他们被认为复发风险较高。我们试图探讨儿童 T-ALL 诊断时初始中枢神经系统(CNS)疾病与生存期缩短之间的相关性。
对 48 例 T-ALL 患儿进行了回顾性分析。该组包括 32 名男孩和 16 名女孩,中位年龄为 8 岁。他们的 CNS 状态分为 CNS-1(脑脊液(CSF)中无原始细胞;n = 44)、CNS-2(CSF 中每微升白细胞数<5 且有原始细胞;n = 0)或 CNS-3(CSF 中每微升白细胞数≥5 且有原始细胞或有 CNS 受累迹象;n = 4)。对于单因素预后分析,我们使用对数秩检验来确定患者特征(年龄、性别、淋巴瘤表现、初始白细胞计数、CNS 疾病和新的治疗策略)对各点的影响。
87.5%的患者诱导获得完全缓解。中位生存期为 37 个月,5 年总生存率和无病生存率分别为 49.5%±8.1%和 47.1%±8.2%。无初始 CNS 受累的患者总体生存期似乎有延长的趋势(P = 0.036)。无病生存不受年龄、白细胞计数或其他分析因素的影响。
初始 CNS 受累的患者预后比无 CNS 疾病的患者差。早期有效的 CNS 定向治疗的引入可能不再预示着 CNS 白血病预后不良。